Drugs / Td-Impfstoff Merieux
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05480462 Comparator | Dec 2022 → Mar 2024 | diphtheria, tetanus | IBSS Biomed S.A. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Td-Impfstoff Mérieux | “Td-Impfstoff Mérieux (Sanofi Pasteur)” NCT05480462 ↗ |
| Modality | Vaccine | “booster immunization with bivalent vaccine against tetanus and diphtheria CLODIVAC (IBSS BIOMED S.A.) and Td-Impfstoff Mérieux (Sanofi Pasteur)” NCT05480462 ↗ |
| Route | Intramuscular | “One dose (0.5 ml) intramuscular” NCT05480462 ↗ |